WO2014200773A3 - Compositions and methods for treating anemia - Google Patents

Compositions and methods for treating anemia Download PDF

Info

Publication number
WO2014200773A3
WO2014200773A3 PCT/US2014/040889 US2014040889W WO2014200773A3 WO 2014200773 A3 WO2014200773 A3 WO 2014200773A3 US 2014040889 W US2014040889 W US 2014040889W WO 2014200773 A3 WO2014200773 A3 WO 2014200773A3
Authority
WO
WIPO (PCT)
Prior art keywords
anemia
compositions
methods
treating anemia
treating
Prior art date
Application number
PCT/US2014/040889
Other languages
French (fr)
Other versions
WO2014200773A2 (en
Inventor
Robert Shalwitz
Charlotte HARTMAN
Akshay BUCH
Isaiah SHALWITZ
John JANUSZ
Joseph Gardner
Original Assignee
Akebia Therapeutics , Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to RU2016100363A priority Critical patent/RU2705206C2/en
Priority to KR1020247012967A priority patent/KR20240055172A/en
Priority to ES14811317T priority patent/ES2974273T3/en
Priority to CN201480045048.2A priority patent/CN105451739A/en
Priority to EP14811317.8A priority patent/EP3007695B1/en
Priority to MX2015017229A priority patent/MX2015017229A/en
Priority to FIEP14811317.8T priority patent/FI3007695T3/en
Priority to LTEPPCT/US2014/040889T priority patent/LT3007695T/en
Priority to CN202111479746.1A priority patent/CN114404414A/en
Priority to EP24156067.1A priority patent/EP4360706A3/en
Priority to KR1020217011294A priority patent/KR102461176B1/en
Priority to SG11201509998WA priority patent/SG11201509998WA/en
Application filed by Akebia Therapeutics , Inc. filed Critical Akebia Therapeutics , Inc.
Priority to SI201432066T priority patent/SI3007695T1/en
Priority to US14/897,849 priority patent/US11857543B2/en
Priority to JP2016519543A priority patent/JP2016521747A/en
Priority to BR112015031027A priority patent/BR112015031027A2/en
Priority to RS20240271A priority patent/RS65341B1/en
Priority to AU2014278543A priority patent/AU2014278543B2/en
Priority to CA2914662A priority patent/CA2914662C/en
Priority to KR1020167000558A priority patent/KR102373245B1/en
Priority to KR1020227037446A priority patent/KR102660040B1/en
Priority to MA38670A priority patent/MA38670B2/en
Priority to MA43609A priority patent/MA43609B1/en
Priority to NZ714963A priority patent/NZ714963A/en
Priority to PE2020000452A priority patent/PE20201496A1/en
Priority to MX2020006963A priority patent/MX2020006963A/en
Priority to DK14811317.8T priority patent/DK3007695T3/en
Priority to HRP20240319TT priority patent/HRP20240319T1/en
Priority to CN202111479723.0A priority patent/CN114404413A/en
Publication of WO2014200773A2 publication Critical patent/WO2014200773A2/en
Publication of WO2014200773A3 publication Critical patent/WO2014200773A3/en
Priority to PH12015502738A priority patent/PH12015502738B1/en
Priority to ZA2015/09024A priority patent/ZA201509024B/en
Priority to IL24304715A priority patent/IL243047B/en
Priority to CR20150660A priority patent/CR20150660A/en
Priority to HK16104721.0A priority patent/HK1216844A1/en
Priority to IL270335A priority patent/IL270335B/en
Priority to AU2020200903A priority patent/AU2020200903B2/en
Priority to PH12020551705A priority patent/PH12020551705A1/en
Priority to IL281058A priority patent/IL281058B2/en
Priority to AU2022200570A priority patent/AU2022200570B2/en
Priority to NO2024025C priority patent/NO2024025I1/en
Priority to FIC20240023C priority patent/FIC20240023I1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.
PCT/US2014/040889 2013-06-13 2014-06-04 Compositions and methods for treating anemia WO2014200773A2 (en)

Priority Applications (41)

Application Number Priority Date Filing Date Title
KR1020227037446A KR102660040B1 (en) 2013-06-13 2014-06-04 Compositions and methods for treating anemia
ES14811317T ES2974273T3 (en) 2013-06-13 2014-06-04 Compositions and methods for treating anemia
KR1020247012967A KR20240055172A (en) 2013-06-13 2014-06-04 Compositions and methods for treating anemia
EP14811317.8A EP3007695B1 (en) 2013-06-13 2014-06-04 Compositions and methods for treating anemia
MX2015017229A MX2015017229A (en) 2013-06-13 2014-06-04 Compositions and methods for treating anemia.
FIEP14811317.8T FI3007695T3 (en) 2013-06-13 2014-06-04 Compositions and methods for treating anemia
LTEPPCT/US2014/040889T LT3007695T (en) 2013-06-13 2014-06-04 Compositions and methods for treating anemia
CN202111479746.1A CN114404414A (en) 2013-06-13 2014-06-04 Compositions and methods for treating anemia
EP24156067.1A EP4360706A3 (en) 2014-06-04 Compositions and methods for treating anemia
KR1020167000558A KR102373245B1 (en) 2013-06-13 2014-06-04 Compositions and methods for treating anemia
SG11201509998WA SG11201509998WA (en) 2013-06-13 2014-06-04 Compositions and methods for treating anemia
MA38670A MA38670B2 (en) 2013-06-13 2014-06-04 Compositions and methods of treatment of anemia
SI201432066T SI3007695T1 (en) 2013-06-13 2014-06-04 Compositions and methods for treating anemia
US14/897,849 US11857543B2 (en) 2013-06-13 2014-06-04 Compositions and methods for treating anemia
JP2016519543A JP2016521747A (en) 2013-06-13 2014-06-04 Compositions and methods for the treatment of anemia
BR112015031027A BR112015031027A2 (en) 2013-06-13 2014-06-04 USE OF A COMPOUND, IN VITRO METHOD, PHARMACEUTICAL COMPOSITION AND SINGLE DOSAGE FORM
RS20240271A RS65341B1 (en) 2013-06-13 2014-06-04 Compositions and methods for treating anemia
AU2014278543A AU2014278543B2 (en) 2013-06-13 2014-06-04 Compositions and methods for treating anemia
CA2914662A CA2914662C (en) 2013-06-13 2014-06-04 Compositions and methods for treating anemia
KR1020217011294A KR102461176B1 (en) 2013-06-13 2014-06-04 Compositions and methods for treating anemia
CN201480045048.2A CN105451739A (en) 2013-06-13 2014-06-04 Compositions and methods for treating anemia
RU2016100363A RU2705206C2 (en) 2013-06-13 2014-06-04 Compositions and methods of treating anaemia
MA43609A MA43609B1 (en) 2013-06-13 2014-06-04 Compositions and methods for treating anemia
NZ714963A NZ714963A (en) 2013-06-13 2014-06-04 Compositions and methods for treating anemia
PE2020000452A PE20201496A1 (en) 2013-06-13 2014-06-04 COMPOSITIONS AND METHODS TO TREAT ANEMIA
MX2020006963A MX2020006963A (en) 2013-06-13 2014-06-04 Compositions and methods for treating anemia.
DK14811317.8T DK3007695T3 (en) 2013-06-13 2014-06-04 COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANEMIA
HRP20240319TT HRP20240319T1 (en) 2013-06-13 2014-06-04 Compositions and methods for treating anemia
CN202111479723.0A CN114404413A (en) 2013-06-13 2014-06-04 Compositions and methods for treating anemia
PH12015502738A PH12015502738B1 (en) 2013-06-13 2015-12-07 Compositions and methods for treating anemia
ZA2015/09024A ZA201509024B (en) 2013-06-13 2015-12-10 Compositions and methods for treating anemia
IL24304715A IL243047B (en) 2013-06-13 2015-12-10 Compositions and methods for treating anemia
CR20150660A CR20150660A (en) 2013-06-13 2015-12-11 COMPOSITIONS AND METHODS TO TREAT ANEMIA
HK16104721.0A HK1216844A1 (en) 2013-06-13 2016-04-25 Compositions and methods for treating anemia
IL270335A IL270335B (en) 2013-06-13 2019-10-31 Compositions and methods for treating anemia
AU2020200903A AU2020200903B2 (en) 2013-06-13 2020-02-07 Compositions and methods for treating anemia
PH12020551705A PH12020551705A1 (en) 2013-06-13 2020-10-15 Compositions and methods for treating anemia
IL281058A IL281058B2 (en) 2013-06-13 2021-02-23 Compositions and methods for treating anemia
AU2022200570A AU2022200570B2 (en) 2013-06-13 2022-01-28 Compositions and methods for treating anemia
NO2024025C NO2024025I1 (en) 2013-06-13 2024-05-29 Vada dust state
FIC20240023C FIC20240023I1 (en) 2013-06-13 2024-06-25 Vadadustat

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201361834808P 2013-06-13 2013-06-13
US61/834,808 2013-06-13
US201361889478P 2013-10-10 2013-10-10
US61/889,478 2013-10-10
US201361898885P 2013-11-01 2013-11-01
US201361898890P 2013-11-01 2013-11-01
US61/898,885 2013-11-01
US61/898,890 2013-11-01
US201361912185P 2013-12-05 2013-12-05
US61/912,185 2013-12-05

Publications (2)

Publication Number Publication Date
WO2014200773A2 WO2014200773A2 (en) 2014-12-18
WO2014200773A3 true WO2014200773A3 (en) 2015-03-05

Family

ID=52022903

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/040889 WO2014200773A2 (en) 2013-06-13 2014-06-04 Compositions and methods for treating anemia

Country Status (31)

Country Link
US (1) US11857543B2 (en)
EP (1) EP3007695B1 (en)
JP (5) JP2016521747A (en)
KR (4) KR20240055172A (en)
CN (3) CN105451739A (en)
AU (3) AU2014278543B2 (en)
BR (1) BR112015031027A2 (en)
CA (2) CA2914662C (en)
CL (2) CL2015003602A1 (en)
DK (1) DK3007695T3 (en)
DO (1) DOP2015000297A (en)
EC (1) ECSP20058592A (en)
ES (1) ES2974273T3 (en)
FI (2) FI3007695T3 (en)
HK (1) HK1216844A1 (en)
HR (1) HRP20240319T1 (en)
IL (3) IL243047B (en)
LT (1) LT3007695T (en)
MX (3) MX2020006963A (en)
NO (1) NO2024025I1 (en)
NZ (3) NZ714963A (en)
PE (2) PE20201496A1 (en)
PH (2) PH12015502738B1 (en)
PT (1) PT3007695T (en)
RS (1) RS65341B1 (en)
RU (2) RU2019134558A (en)
SG (2) SG10201910773VA (en)
SI (1) SI3007695T1 (en)
TW (4) TWI712411B (en)
WO (1) WO2014200773A2 (en)
ZA (1) ZA201509024B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107645953A (en) * 2015-04-01 2018-01-30 阿克比治疗有限公司 For treating the composition and method of anaemia

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5113838B2 (en) 2006-06-26 2013-01-09 アケビア セラピューティックス， インコーポレイテッド Prolyl hydroxylase inhibitors and methods of use
NO2686520T3 (en) 2011-06-06 2018-03-17
EP2986207B1 (en) 2013-04-16 2024-03-20 Koninklijke Philips N.V. System and method for biventricular pacemaker pulse detection in surface ecg
RS65341B1 (en) * 2013-06-13 2024-04-30 Akebia Therapeutics Inc Compositions and methods for treating anemia
MA39033A1 (en) 2013-11-15 2017-11-30 Akebia Therapeutics Inc Solid forms of {[5- (3-chlorophenyl) -3-hydroxypyridine-2-carbonyl] amino} acetic acid, compositions and uses thereof
WO2016118858A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
WO2018103600A1 (en) * 2016-12-06 2018-06-14 深圳市塔吉瑞生物医药有限公司 Substituted heteroaryl amide compound and composition comprising same and use thereof
WO2019028150A1 (en) * 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. Compositions for use in methods of treatment of hemoglobin disorders
AR114886A1 (en) 2018-05-09 2020-10-28 Akebia Therapeutics Inc PROCESS TO PREPARE 2 - [[5- (3-CHLOROPHENYL) -3-HYDROXYPYRIDIN-2-CARBONYL] AMINO] ACETIC ACID
WO2021087144A1 (en) 2019-10-31 2021-05-06 Akebia Therapeutics, Inc. Therapeutic methods using vadadustat
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
CN115279342A (en) * 2020-03-17 2022-11-01 兹杜斯生命科学有限公司 Formulations comprising HIF prolyl hydroxylase inhibitors
US20210353612A1 (en) * 2020-04-29 2021-11-18 BioAge Labs, Inc. Hypoxia-inducible factor prolyl hydroxylase inhibitors for treating aging-related conditions
JP2023530452A (en) 2020-06-19 2023-07-18 アケビア セラピューティクス インコーポレイテッド Modulation of drug-drug interactions of vadadustat
EP4274575A1 (en) 2021-01-08 2023-11-15 Akebia Therapeutics Inc. Therapeutic methods using vadadustat
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
IL305487A (en) 2021-03-01 2023-10-01 Akebia Therapeutics Inc Modulation of drug-drug interactions of vadadustat

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070299086A1 (en) * 2006-06-26 2007-12-27 The Procter & Gamble Company Prolyl hydroxylase inhibitors and methods of use
US20120309977A1 (en) * 2011-06-06 2012-12-06 Akebia Therapeutics Inc. Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655679A (en) 1969-06-25 1972-04-11 Merck & Co Inc Certain aryl pyridine carboxylic acid derivatives
US3703582A (en) 1970-04-20 1972-11-21 Merck & Co Inc Aryl pyridine carboxylic acids in the treatment of inflammation
US3894920A (en) 1971-12-21 1975-07-15 Sagami Chem Res Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
US4016287A (en) 1972-07-17 1977-04-05 Boehringer Ingelheim Gmbh Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
CA1261335A (en) 1984-08-29 1989-09-26 Hoffmann-La Roche Limited/Hoffmann-La Roche Limitee Ethylenediamine monoamide derivatives
TW219933B (en) 1990-02-26 1994-02-01 Lilly Co Eli
US5405613A (en) 1991-12-11 1995-04-11 Creative Nutrition Canada Corp. Vitamin/mineral composition
TW352384B (en) 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4219158A1 (en) 1992-06-11 1993-12-16 Thomae Gmbh Dr K Biphenyl derivatives, pharmaceutical compositions containing them and processes for their preparation
DK0650961T3 (en) 1993-11-02 1997-09-15 Hoechst Ag Substituted heterocyclic carboxylic acid amides, their preparation and their use as drugs.
ES2101420T3 (en) 1993-11-02 1997-07-01 Hoechst Ag ESTERS-AMIDES OF SUBSTITUTED HETERO-CYCLIC CARBOXYL ACIDS, THEIR PREPARATION AND THEIR USE AS MEDICINES.
TW406076B (en) 1993-12-30 2000-09-21 Hoechst Ag Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
DE4410423A1 (en) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carboxamides and their pyridine N-oxides, processes for their preparation and their use as medicaments
DE4410480A1 (en) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridine-2-carboxylic acid ester amides and their pyridine N-oxides, processes for their preparation and their use as medicaments
US5789426A (en) 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
DE19535571A1 (en) 1995-09-14 1997-03-20 Boehringer Mannheim Gmbh Combined pharmaceutical preparations and their use for the treatment of hemodialysis patients
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of substituted quinoline-2-carboxylic acid amides
JPH09221476A (en) 1995-12-15 1997-08-26 Otsuka Pharmaceut Co Ltd Medicinal composition
KR20000065090A (en) 1996-04-30 2000-11-06 훽스트 악티엔게젤샤프트 3-alkoxypyridine-2-carboxylic acid amide ester, preparation method thereof and its use as a pharmaceutical
DE19620041A1 (en) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhesion receptor antagonists
DE19650215A1 (en) 1996-12-04 1998-06-10 Hoechst Ag 3-hydroxypyridine-2-carboxylic acid amide esters, their preparation and their use as medicaments
US6420427B1 (en) 1997-10-09 2002-07-16 Ono Pharmaceutical Co., Ltd. Aminobutyric acid derivatives
DE19746287A1 (en) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituted isoquinoline-2-carboxylic acid amides, their preparation and their use as medicaments
DE69919349T2 (en) 1998-03-23 2005-01-13 Aventis Pharmaceuticals Inc. PIPERIDINYL AND N-AMIDINOPIPERIDINYL DERIVATIVES
GB9809213D0 (en) 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
ES2277682T3 (en) 1998-06-11 2007-07-16 PHARMACIA & UPJOHN COMPANY LLC FORMULATION OF DELAVIRDINE IN COMPRESSED.
US6159379A (en) 1999-05-04 2000-12-12 Baker Hughes Incorporated Organic ammonium salts for the removal of water soluble organics in produced water
JP2001048786A (en) 1999-08-05 2001-02-20 Yamanouchi Pharmaceut Co Ltd Tricyclic heteroaryl derivative
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
US7964216B2 (en) 2001-01-12 2011-06-21 Sun Pharma Advanced Research Company Limited Spaced drug delivery system
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US20040146964A1 (en) 2001-03-21 2004-07-29 Maxwell Patrick Henry Assays, methods and means
SE0101327D0 (en) 2001-04-12 2001-04-12 Astrazeneca Ab New crystalline forms
US6566088B1 (en) 2001-10-04 2003-05-20 Board Of Regents, The University Of Texas System Prolyl-4-hydroxylases
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
US20030176317A1 (en) * 2001-12-06 2003-09-18 Volkmar Guenzler-Pukall Stabilization of hypoxia inducible factor (HIF) alpha
NZ536908A (en) 2002-05-17 2008-09-26 Celgene Corp Treating or preventing cancer comprising administering an effective amount of cytokine inhibitory drug plus a second active ingredient
WO2003101431A1 (en) * 2002-06-04 2003-12-11 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
KR20050033660A (en) 2002-08-29 2005-04-12 머크 앤드 캄파니 인코포레이티드 N-biarylmethyl aminocycloalkanecarboxamide derivatives
ATE452204T1 (en) 2002-10-16 2010-01-15 Isis Innovation SCREENING METHODS USING A STRUCTURAL MODEL OF FIH
EP1567528A1 (en) 2002-11-21 2005-08-31 Eli Lilly And Company Mixed lineage kinase modulators
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
CN102977015B (en) 2003-06-06 2015-05-06 菲布罗根有限公司 Nitrogen-containing heteroaryl compounds and their use in increasing endogeneous erythropoietin
US20060251638A1 (en) 2003-06-06 2006-11-09 Volkmar Guenzler-Pukall Cytoprotection through the use of hif hydroxylase inhibitors
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
ES2332798T3 (en) 2004-05-28 2010-02-12 Fibrogen, Inc. ACTIVITY TEST OF HIFROXYLASE PROLIL HIF.
JP2008500951A (en) 2004-05-31 2008-01-17 田辺三菱製薬株式会社 Bicyclic compounds
CA2573185A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
TW200616969A (en) 2004-09-17 2006-06-01 Tanabe Seiyaku Co Imidazole compound
US20080213404A1 (en) 2005-02-04 2008-09-04 Johnson Randall S Hif Modulating Compounds and Methods of Use Thereof
DE102005019712A1 (en) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone and its use
WO2006133391A2 (en) 2005-06-06 2006-12-14 Fibrogen, Inc. Improved treatment for anemia using a hif-alpha stabilising agent
BRPI0611670A2 (en) 2005-06-15 2016-11-16 Fibrogen Inc method for treating or preventing cancer in an individual
RU2424805C2 (en) 2005-09-12 2011-07-27 Актелион Фармасьютиклз Лтд Stable pharmaceutical pyrimidinsulfamide-including compositions
WO2007033216A2 (en) 2005-09-12 2007-03-22 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
WO2007047194A2 (en) 2005-10-11 2007-04-26 Dana-Farber Cancer Institute, Inc. Methods for treating mitf-related disorders
ES2446416T3 (en) 2005-12-09 2014-03-07 Amgen, Inc. Quinolone-based compounds that have prolyl hydroxylase inhibitory activity, compositions and uses thereof
EP1971618A2 (en) 2006-01-09 2008-09-24 Btg International Limited Modulators of hypoxia inducible factor-1 and related uses
WO2007082899A1 (en) 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
JP4801451B2 (en) 2006-01-19 2011-10-26 株式会社日立ハイテクノロジーズ Control device and control method for electron gun used in scanning electron microscope and the like
CA2635899A1 (en) 2006-01-19 2007-07-26 Osi Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
ITMI20060179A1 (en) 2006-02-02 2007-08-03 Abiogen Pharma Spa PROCEDURE FOR RESOLUTION OF RACEMIC MIXTURES AND DIASTEREOISOMERIC COMPLEX OF A SOLVING AGENT AND UNANTIOMER OF INTEREST
US7625927B2 (en) 2006-02-27 2009-12-01 Alcon Research, Ltd. Method of treating glaucoma
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
PE20071020A1 (en) 2006-03-07 2007-12-11 Smithkline Beecham Corp N-SUBSTITUTED GLYCINE DERIVATIVE COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS
US20090176825A1 (en) 2006-05-16 2009-07-09 Fitch Duke M Prolyl hydroxylase inhibitors
KR100798730B1 (en) * 2006-06-12 2008-01-29 신풍제약주식회사 Controlled release formulation containing loxoprofen or zaltoprofen and process for the preparation thereof
JO2934B1 (en) 2006-06-23 2015-09-15 سميث كلاين بيتشام كوربوريشن Prolyl Hydroxylase Inhibitors
CA2563690C (en) 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
IES20070122A2 (en) 2006-12-05 2008-05-28 Michael Hilary Burke A process for the preparation of an orally administered unit dose tablet
CL2008000065A1 (en) 2007-01-12 2008-09-22 Smithkline Beecham Corp COMPOUNDS DERIVED FROM N-SUBSTITUTED GLYCINE, INHIBITORS OF HIF PROLIL HYDROXYLASES; YOUR PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE IN THE TREATMENT OF THE ANEMIA.
CL2008000066A1 (en) 2007-01-12 2008-08-01 Smithkline Beecham Corp COMPOUNDS DERIVED FROM (5-HYDROXY-3-OXO-2,3-DIHYDROPIRIDAZINE-4-CARBONYL) GLYCINE, HIFROXYLASE HYDROXYLASE HIF INHIBITORS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE IN THE TREATMENT OF THE ANEM
WO2008125388A1 (en) 2007-04-17 2008-10-23 Ratiopharm Gmbh Pharmaceutical compositions comprising irbesartan
WO2008130527A1 (en) 2007-04-18 2008-10-30 Merck & Co., Inc. Novel 1,8-naphthyridine compounds
US7569726B2 (en) 2007-04-18 2009-08-04 Amgen Inc. Indanone derivatives that inhibit prolyl hydroxylase
WO2008137060A1 (en) 2007-05-04 2008-11-13 Amgen Inc. Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
EP2160187B1 (en) 2007-05-16 2013-05-22 Merck Sharp & Dohme Corp. Spiroindalones
RU2009146851A (en) 2007-05-18 2011-06-27 Байер Шеринг Фарма Акциенгезельшафт (DE) Heteroaryl-Substituted Pyrazole Derivatives Which May Be Used for the Treatment of Hyperproliferative Disorders and Diseases Associated with Angiogenesis
WO2009020119A1 (en) 2007-08-06 2009-02-12 Senju Pharmaceutical Co., Ltd. Pharmaceutical containing hif-1 alpha and hif-2 alpha expression inhibitor
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
CA2696725A1 (en) 2007-08-10 2009-03-26 Crystalgenomics, Inc. Pyridine derivatives and methods of use thereof
WO2009035534A2 (en) 2007-09-07 2009-03-19 The Cleveland Clinic Foundation Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
WO2009039321A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009043093A1 (en) 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009067790A1 (en) 2007-11-26 2009-06-04 Uti Limited Partnership STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
AU2008331480A1 (en) 2007-11-30 2009-06-11 Glaxosmithkline Llc Prolyl hydroxylase inhibitors
EP2224926A4 (en) 2007-11-30 2010-12-01 Glaxosmithkline Llc Prolyl hydroxylase inhibitors
WO2009073669A1 (en) 2007-12-03 2009-06-11 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
US20100298324A1 (en) 2007-12-19 2010-11-25 Smith Kline Beecham Corporation Prolyl Hydroxylase Inhibitors
US20110003013A1 (en) 2008-01-04 2011-01-06 Garvan Institute Of Medical Research Method of increasing metabolism
WO2009089547A1 (en) 2008-01-11 2009-07-16 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
WO2009111337A1 (en) 2008-03-03 2009-09-11 Irm Llc Compounds and compositions as tlr activity modulators
PE20110409A1 (en) 2008-07-23 2011-06-22 Hoffmann La Roche HETEROCYCLIC ANTIVIRIC COMPOUNDS
TW201006473A (en) * 2008-08-13 2010-02-16 Orient Pharma Co Ltd Bi-layer medicine tablet containing Zaleplon
CN102149703B (en) 2008-09-15 2014-09-10 卡斯娜莱拉伊诺制药私人有限公司 Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers
HU230877B1 (en) * 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stable pharmaceutical combination
CN105037323A (en) 2008-11-14 2015-11-11 菲布罗根有限公司 Thiochromene derivatives as HIF hydroxylase inhibitors
US8137666B2 (en) * 2008-11-22 2012-03-20 Academia Sinica Nattokinase for degrading and reducing amyloid fibrils—associated with alzheimer's disease, prion diseases and other amyloidoses
WO2010114801A1 (en) 2009-03-31 2010-10-07 Ligand Pharmaceuticals Inc. Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy
MX2011010395A (en) 2009-03-31 2011-10-24 Kissei Pharmaceutical Indolizine derivative and use thereof for medical purposes.
CA2768505C (en) 2009-07-17 2018-06-12 Japan Tobacco Inc. Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer
EP2496236B1 (en) 2009-11-06 2013-05-01 Aerpio Therapeutics Inc. Prolyl hydroxylase inhibitors
WO2012097331A1 (en) 2011-01-13 2012-07-19 Fibrogen, Inc. Methods for increasing reticulocyte hemoglobin content
US8865748B2 (en) 2011-06-06 2014-10-21 Akebia Therapeutics Inc. Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
US20130022974A1 (en) 2011-06-17 2013-01-24 The Regents Of The University Of Michigan Dna methylation profiles in cancer
US9206134B2 (en) 2011-07-22 2015-12-08 Beijing Betta Pharmaceuticals Co. Ltd. Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
US11491154B2 (en) 2013-04-08 2022-11-08 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
RS65341B1 (en) 2013-06-13 2024-04-30 Akebia Therapeutics Inc Compositions and methods for treating anemia
RU2016109125A (en) 2013-08-16 2017-09-22 Огайо Стейт Инновейшн Фаундейшн COMPOSITIONS AND METHODS OF MODULATION OF DNA METHYLING
MA39033A1 (en) 2013-11-15 2017-11-30 Akebia Therapeutics Inc Solid forms of {[5- (3-chlorophenyl) -3-hydroxypyridine-2-carbonyl] amino} acetic acid, compositions and uses thereof
EP3096617A4 (en) 2014-01-23 2017-09-13 Akebia Therapeutics Inc. Compositions and methods for treating ocular diseases
WO2016118858A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
EP3270922A4 (en) 2015-03-20 2018-08-01 Akebia Therapeutics Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
PL3277270T3 (en) 2015-04-01 2022-02-14 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
WO2019028150A1 (en) 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. Compositions for use in methods of treatment of hemoglobin disorders
KR20210100594A (en) 2018-10-03 2021-08-17 아케비아 테라퓨틱스 인코포레이티드 Benzoimidazole derivatives for use in the treatment of inflammatory disorders
US11524939B2 (en) * 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070299086A1 (en) * 2006-06-26 2007-12-27 The Procter & Gamble Company Prolyl hydroxylase inhibitors and methods of use
US20140057892A1 (en) * 2006-06-26 2014-02-27 Akebia Therapeutics, Inc. Prolyl hydroxylase inhibitors and methods of use
US20120309977A1 (en) * 2011-06-06 2012-12-06 Akebia Therapeutics Inc. Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"AKEBIA CLOSES $41 MILLION SERIES C", 4 June 2013 (2013-06-04), pages 1 - 2, XP026740630, Retrieved from the Internet <URL:hftp://www.tmvp.com/news_Akebia_06042013.html> *
"CLINICALTRIALS.GOV: ARCHIVE: NCT01235936 Nn 2012_09_30", 30 August 2012 (2012-08-30), pages 1 - 3, XP055328354, Retrieved from the Internet <URL:http://clinicaltrials.gov/archive/NCT01235936/2012_09_30> *
PASQUALETTI, P ET AL.: "Circadian Rhythm Of Serum Erythropoietin In Myelodysplastic Syndromes.", EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES., vol. 4, 2000, pages 111 - 115, XP055303710 *
STOHLAWETZ, PJ ET AL.: "Effects Of Erythropoietin On Platelet Reactivity And Thrombopoiesis In Humans.", BLOOD., vol. 95, no. 9, 2000, pages 2983 - 2989, XP002481264 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107645953A (en) * 2015-04-01 2018-01-30 阿克比治疗有限公司 For treating the composition and method of anaemia

Also Published As

Publication number Publication date
EP3007695B1 (en) 2024-02-07
DK3007695T3 (en) 2024-03-18
AU2020200903B2 (en) 2021-11-04
PH12015502738A1 (en) 2016-03-07
IL243047B (en) 2019-11-28
JP2019163293A (en) 2019-09-26
CL2018002372A1 (en) 2018-12-28
US11857543B2 (en) 2024-01-02
WO2014200773A2 (en) 2014-12-18
IL270335B (en) 2021-03-25
KR20210043760A (en) 2021-04-21
US20160143891A1 (en) 2016-05-26
MX2022003510A (en) 2022-05-16
NZ753904A (en) 2020-07-31
NZ714963A (en) 2020-07-31
PE20160194A1 (en) 2016-04-20
AU2014278543B2 (en) 2019-11-14
AU2022200570B2 (en) 2024-05-02
ECSP20058592A (en) 2020-10-30
DOP2015000297A (en) 2016-03-15
CN105451739A (en) 2016-03-30
KR102373245B1 (en) 2022-03-17
JP2023145717A (en) 2023-10-11
TW202339743A (en) 2023-10-16
SI3007695T1 (en) 2024-04-30
KR20220151008A (en) 2022-11-11
EP4360706A2 (en) 2024-05-01
CA3151685A1 (en) 2014-12-18
FI3007695T3 (en) 2024-03-13
TWI712411B (en) 2020-12-11
NO2024025I1 (en) 2024-05-29
RU2016100363A (en) 2017-07-18
SG10201910773VA (en) 2020-01-30
EP3007695A4 (en) 2017-05-31
KR102660040B1 (en) 2024-04-24
TW202133843A (en) 2021-09-16
CN114404413A (en) 2022-04-29
CN114404414A (en) 2022-04-29
IL281058B1 (en) 2023-04-01
MX2015017229A (en) 2016-04-19
CA2914662A1 (en) 2014-12-18
TWI650126B (en) 2019-02-11
JP2016521747A (en) 2016-07-25
MX2020006963A (en) 2022-03-30
ES2974273T3 (en) 2024-06-26
AU2020200903A1 (en) 2020-02-27
EP3007695A2 (en) 2016-04-20
PT3007695T (en) 2024-03-07
RS65341B1 (en) 2024-04-30
NZ753905A (en) 2020-07-31
RU2019134558A (en) 2020-02-20
LT3007695T (en) 2024-03-25
JP6612479B2 (en) 2019-11-27
PH12020551705A1 (en) 2021-11-15
IL281058B2 (en) 2023-08-01
JP7328291B2 (en) 2023-08-16
KR102461176B1 (en) 2022-11-01
KR20160023773A (en) 2016-03-03
CA2914662C (en) 2022-05-31
JP2020033369A (en) 2020-03-05
AU2014278543A1 (en) 2016-01-07
CL2015003602A1 (en) 2016-07-29
ZA201509024B (en) 2019-05-29
SG11201509998WA (en) 2016-01-28
PE20201496A1 (en) 2020-12-29
HK1216844A1 (en) 2016-12-09
HRP20240319T1 (en) 2024-05-24
BR112015031027A2 (en) 2017-08-29
TW201534302A (en) 2015-09-16
PH12015502738B1 (en) 2016-03-07
TWI791177B (en) 2023-02-01
JP2021191773A (en) 2021-12-16
AU2022200570A1 (en) 2022-02-17
KR20240055172A (en) 2024-04-26
FIC20240023I1 (en) 2024-06-25
RU2016100363A3 (en) 2018-05-15
RU2705206C2 (en) 2019-11-06
IL281058A (en) 2021-04-29
TW201922244A (en) 2019-06-16
JP6937812B2 (en) 2021-09-22

Similar Documents

Publication Publication Date Title
PH12020551705A1 (en) Compositions and methods for treating anemia
ZA202006107B (en) Compositions and methods for treating anemia
EP3191098A4 (en) Combinations and dosing regimes to treat rb-positive tumors
EP3154596A4 (en) Anti-cancer effects of proteasome inhibitors in combination with glucocorticoids, arsenic containing compounds, and ascorbic acid
TN2017000435A1 (en) [bis(trihydrocarbylsilyl)aminosilyl]-functionalized styrene and a method for its preparation
EP3197455A4 (en) Inhibitors of hif prolyl hydroxylase
WO2013149171A3 (en) Methods for increasing efficacy of cd37-based therapy
WO2014197885A3 (en) Inhibitors of complement factor h
WO2014151606A3 (en) Methods of treating pancreatic cancer
EP3197900A4 (en) Inhibitors of hif prolyl hydroxylase
WO2014146111A3 (en) Analgesic compounds and methods of use
EP3197451A4 (en) Inhibitors of hif prolyl hydroxylase
IN2014DE02625A (en)
UA117455C2 (en) METHOD OF TREATMENT OF LUNG CANCER WITH APPLICATION OF AUROR KINAS INHIBITOR
EP3197452A4 (en) Inhibitors of hif prolyl hydroxylase
EP3204363A4 (en) Substituted pyrimidines as inhibitors of hif prolyl hydroxylase
EP3204385A4 (en) Substituted pyrimidines as inhibitors of hif prolyl hydroxylase
EP4360706A3 (en) Compositions and methods for treating anemia
WO2015066439A8 (en) Methods of treating hematological malignancies
CR20150660A (en) COMPOSITIONS AND METHODS TO TREAT ANEMIA
WO2017177216A8 (en) Prodigiosin analogs
AR104157A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF THE ANEMIA
UA88238U (en) Method for extraction-photometric determination of meloxicam

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201480045048.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14811317

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2914662

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12015502738

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: P1642/2015

Country of ref document: AE

WWE Wipo information: entry into national phase

Ref document number: 243047

Country of ref document: IL

Ref document number: IDP00201508375

Country of ref document: ID

Ref document number: 38670

Country of ref document: MA

ENP Entry into the national phase

Ref document number: 2016519543

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 002603-2015

Country of ref document: PE

Ref document number: CR2015-000660

Country of ref document: CR

Ref document number: MX/A/2015/017229

Country of ref document: MX

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015031027

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2014278543

Country of ref document: AU

Date of ref document: 20140604

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20167000558

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2014811317

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2016100363

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 16006928

Country of ref document: CO

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14811317

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112015031027

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20151210

WWE Wipo information: entry into national phase

Ref document number: P-2024/0271

Country of ref document: RS